News
ANIK
25.54
+0.71%
0.18
Weekly Report: what happened at ANIK last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at ANIK last week (0311-0315)?
Weekly Report · 03/18 09:09
Anika Therapeutics Price Target Raised to $37.00/Share From $29.00 by Barrington Research
Dow Jones · 03/14 14:26
Anika Therapeutics Is Maintained at Outperform by Barrington Research
Dow Jones · 03/14 14:26
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $37
Benzinga · 03/14 14:15
Anika Therapeutics: Strong Q4 Performance and Upbeat FY2024 Outlook Justify Buy Rating and Raised Price Target
TipRanks · 03/14 14:15
Anika Therapeutics Price Target Maintained With a $22.00/Share by Stephens & Co.
Dow Jones · 03/14 14:05
Stephens & Co. Reiterates Equal-Weight on Anika Therapeutics, Maintains $22 Price Target
Benzinga · 03/14 13:55
Anika Therapeutics to reduce workforce by 9%
Anika Therapeutics to reduce workforce by 9% The company stock price gained 6.30% on Thursday during pre-market hours of trading after its Q4 results beat consensus. The cost reductions are expected to provide savings of $10M. Anika will reduce planned spending for 2024 and to reduce 9% of its workforce.
Seeking Alpha · 03/14 07:10
Anika Therapeutics to Cut Workforce by 9% in Push for Profitability
Anika Therapeutics will reduce its workforce by 9%. The orthopedic and regenerative medicines company said the reductions are effective at the end of the first quarter. The company expects savings on an annualized basis of about $10 million. Company says it is prioritizing profitability and slower-than-expected growth.
Dow Jones · 03/13 20:43
Anika Therapeutics: Q4 Earnings Insights
Anika Therapeutics reported its Q4 earnings of $0.05 on Wednesday. The company's revenue was up $3.35 million from the same period last year. AnikaTherapeutics beat estimates by 119.0%. The company is expected to announce its earnings on March 13, 2024.
Benzinga · 03/13 20:40
*Anika Therapeutics Conducted Strategic Review, Evaluating Alternatives to Increase Shareholder Value, Including Potential Sale >ANIK
Dow Jones · 03/13 20:23
*Anika Therapeutics: 'Remains Open to All Value Enhancing Opportunities' >ANIK
Dow Jones · 03/13 20:23
*Anika Therapeutics Sees FY24 Rev $168M-$173M >ANIK
Dow Jones · 03/13 20:22
*Anika Therapeutics to Reduce About 9% of Workforce, Effective End of 1Q >ANIK
Dow Jones · 03/13 20:21
*Anika Therapeutics to Further Reduce Its Planned Spending for 2024 >ANIK
Dow Jones · 03/13 20:21
*Anika Therapeutics Positioned to Generate Adj EBITDA of $25 M to $30 M in 2024 >ANIK
Dow Jones · 03/13 20:20
*Anika Therapeutics: Cost Reduction Initiatives Providing Annual Savings of About $10 M >ANIK
Dow Jones · 03/13 20:20
*Anika Therapeutics 4Q Adj EPS 5c >ANIK
Dow Jones · 03/13 20:05
*Anika Therapeutics 4Q Loss $63M >ANIK
Dow Jones · 03/13 20:05
More
Webull provides a variety of real-time ANIK stock news. You can receive the latest news about Anika Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANIK
Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.